Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | FNTA | P49354 | 7/20 | 0.40 |
| ▸ | FNTB | P49356 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757417 | 0.88 | FNTA (0.43) | CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL6759301 | 0.86 | FNTA (0.54) | CYP11B1CYP11B2FNTAFNTBRAB9A | |
| SCHEMBL6757378 | 0.85 | FNTA (0.44) | CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL6757425 | 0.83 | FNTA (0.41) | CYP11B1CYP11B2FNTAFNTBRAB9A | |
| SCHEMBL6601239 | 0.79 | FNTA (0.41) | CYP11B1CYP11B2FNTAFNTBRAB9A | |
| SCHEMBL6602097 | 0.79 | CYP11B1 (0.42) | CYP11B1CYP11B2FNTAFNTBRAB9A | |
| SCHEMBL6602181 | 0.79 | FNTA (0.41) | CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL6600292 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2FNTAFNTBRAB9A | |
| SCHEMBL6602017 | 0.78 | FNTA (0.45) | CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL6756404 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2FNTAFNTBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | PIERRE FABRE MEDICAMENT (FR) | 2004-10-14 | — | — | US | claimed |
| EP-1395581-A2 | NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, PREPARATION AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS | PIERRE FABRE MEDICAMENT (FR) | 2004-03-10 | — | — | EP | claimed |
| WO-2002098852-A2 | NOVEL BENZOTHIENYL OR INDOLE DERIVATIVES, AND USE THEREOF AS INHIBITORS OF PRENYL TRANSFERASE PROTEINS | PIERRE FABRE MEDICAMENT (FR) | 2002-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | CBR1, CBR3, HCCS | CYP11B1 126/4885CYP11B2 162/4885FNTA 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.